Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tiemonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 15/20 | 0.39 |
| ▸ | CHRM1 known ✓ | P11229 | 12/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 12/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiemonium SCHEMBL250702 | 0.90 | CHRM3 (0.45) | RGS12CHRM3CHRM2CHRM1CHRM4 | |
| Tiemonium SCHEMBL24577 | 0.89 | CHRM3 (0.47) | RGS12CHRM3CHRM2CHRM1CHRM4 | |
| Iodide SCHEMBL3366197 | 0.76 | RGS12 (0.41) | RGS12CHRM3CHRM2CHRM1CHRM4 | |
| Thiphenamil SCHEMBL7749726 | 0.73 | MAPT (0.49) | RGS12CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL3969300 | 0.64 | CTDSP1 (0.45) | GAAAPOBEC3AAPOBEC3GCHRNB2CHRNB4 | |
| SCHEMBL27463664 | 0.64 | CHRM3 (0.42) | RGS12CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL975081 | 0.63 | CDC25A (0.53) | GAAAPOBEC3AAPOBEC3G | |
| SCHEMBL11345454 | 0.63 | CDC25A (0.53) | GAAAPOBEC3AAPOBEC3G | |
| Iodide SCHEMBL29558329 | 0.63 | CHRM2 (0.83) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL17102598 | 0.63 | CDC25A (0.49) | GAAAPOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784194-B2 | FOR INHIBITING EFFECTS OF EXOGENOUS NEUROTOXIC OR NEUROTOXINIC PRODUCTS IN WARM-BLOODED ANIMALS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-08-31 | — | — | US | claimed |
| EP-0956019-B1 | NOVEL THERAPEUTIC APPLICATION OF A THIENYCYCLOHEXYLAMINE DERIVATIVE | SOD CONSEILS RECH APPLIC (FR) | 2003-10-15 | — | — | EP | claimed |
| US-20010056091-A1 | Therapeutic use of a thienylcyclohexylamine derivative | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) | 2001-12-27 | — | — | US | claimed |
| US-6207685-B1 | INHIBITING EFFECTS OF EXOGENOUS NEUROTOXIC OR NEUROTOXINIC PRODUCTS IN WARM-BLOODED ANIMALS BY ADMINISTERING 2-METHYL-1-(1-PIPERIDINYL)-1-(2-THIENYL)-CYCLOHEXANE IN PURE RACEMIC, DIASTEREOISOMERIC OR ENANTIOMERIC FORM | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-03-27 | — | — | US | claimed |
| EP-0956019-A1 | NOVEL THERAPEUTIC APPLICATION OF A THIENYCYCLOHEXYLAMINE DERIVATIVE | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1999-11-17 | — | — | EP | claimed |
| WO-1998024434-A1 | NOVEL THERAPEUTIC APPLICATION OF A THIENYCYCLOHEXYLAMINE DERIVATIVE | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1998-06-11 | — | — | WO | claimed |
| EP-0140434-B1 | PHARMACEUTICAL COMPOSITION WITH SYSTEMIC ANTICHOLINEESTERASIC, AGONISTIC-CHOLINERGIC AND ANTIMUSCARINIC ACTIVITY | PRODOTTI FORMENTI S.r.l. (IT) | 1993-08-04 | — | — | EP | claimed |
| US-9532947-B2 | Formulation for oral transmucosal administration of analgesic and/or antispasmodic molecules | PEROVITCH PHILIPPE (FR) | 2017-01-03 | — | — | US | disclosed |
| EP-2387389-B1 | COMPOSITION FOR ORAL TRANSMUCOSAL ADMINISTRATION OF ANTALGIC OR ANTISPASMODIC AGENTS | PEROVITCH PHILIPPE (FR) | 2016-06-08 | — | — | EP | disclosed |
| EP-2387389-A1 | FORMULATION FOR ORAL TRANSMUCOSAL ADMINISTRATION OF ANALGESIC AND/OR ANTISPASMODIC MOLECULES | Perovitch, Philippe (FR) | 2011-11-23 | — | — | EP | disclosed |
| US-20110275626-A1 | FORMULATION FOR ORAL TRANSMUCOSAL ADMINISTRATION OF ANALGESIC AND/OR ANTISPASMODIC MOLECULES | PEROVITCH PHILIPPE | 2011-11-10 | — | — | US | disclosed |
| US-20110253511-A1 | APPARATUS AND METHOD FOR RECEIVING AND TRANSFERRING SOLID MATERIAL | THE PROCTER & GAMBLE COMPANY (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2010081984-A1 | FORMULATION FOR ORAL TRANSMUCOSAL ADMINISTRATION OF ANALGESIC AND/OR ANTISPASMODIC MOLECULES | PEROVITCH PHILIPPE (FR) | 2010-07-22 | — | — | WO | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| US-6784194-B2 | FOR INHIBITING EFFECTS OF EXOGENOUS NEUROTOXIC OR NEUROTOXINIC PRODUCTS IN WARM-BLOODED ANIMALS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-08-31 | — | — | US | disclosed |
| US-20010056091-A1 | Therapeutic use of a thienylcyclohexylamine derivative | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) | 2001-12-27 | — | — | US | disclosed |
| US-6207685-B1 | INHIBITING EFFECTS OF EXOGENOUS NEUROTOXIC OR NEUROTOXINIC PRODUCTS IN WARM-BLOODED ANIMALS BY ADMINISTERING 2-METHYL-1-(1-PIPERIDINYL)-1-(2-THIENYL)-CYCLOHEXANE IN PURE RACEMIC, DIASTEREOISOMERIC OR ENANTIOMERIC FORM | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-03-27 | — | — | US | disclosed |
| EP-0140434-B1 | PHARMACEUTICAL COMPOSITION WITH SYSTEMIC ANTICHOLINEESTERASIC, AGONISTIC-CHOLINERGIC AND ANTIMUSCARINIC ACTIVITY | PRODOTTI FORMENTI S.r.l. (IT) | 1993-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | CHRM3 2506/4885CHRM1 1417/4885RGS12 4727/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | CHRM3 4509/4885CHRM1 4783/4885RGS12 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.